SecondWave Systems, Inc., an innovative company at the forefront of bio-ultrasonic medicine development, is making significant strides in creating new therapeutic options for rheumatoid arthritis (RA) and other immune-mediated inflammatory conditions. With the appointment of Professor Paul Peter Tak as the first member of its advisory board, SecondWave gains a wealth of experience from a renowned academic physician-scientist and industry leader. Dr. Tak’s groundbreaking work in bioelectronic medicine and autoimmune diseases lends valuable insight into SecondWave’s mission to develop a non-invasive, ultrasound-based treatment modality.
The company has announced securing an additional $3 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) in partnership with the Defense Advanced Research Projects Agency (DARPA), bringing its total non-dilutive U.S. government funding to $15.3 million. This support has been instrumental in the progress of SecondWave’s MINI™ technology platform, a pioneering wearable therapeutic ultrasound stimulation device designed for the personalized treatment of chronic and acute inflammatory disorders.
The second round of funding will facilitate the advancement of the MINI technology for a pivotal clinical trial aimed at at-home treatment of RA. Dr. Tak highlighted the ongoing need for innovative treatments that engage the body’s natural anti-inflammatory mechanisms, such as the cholinergic anti-inflammatory pathway, which SecondWave’s MINI system targets through noninvasive methods.
As SecondWave continues its journey to commercialize the MINI as a novel therapy for inflammatory diseases, the company emphasizes the importance of collaboration with esteemed scientists, clinicians, and government agencies. CEO Anuj Bhardwaj expressed enthusiasm for entering the next development phase with Dr. Tak’s expertise and the sustained backing of DARPA and ARPA-H. SecondWave remains committed to producing comprehensive scientific data to support the efficacy of its distinct therapeutic approach, aiming to meet the significant demand for advanced treatments for chronic inflammatory conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
